Literature DB >> 12935979

Von Willebrand factor cleaving protease (ADAMTS-13) in 123 patients with connective tissue diseases (systemic lupus erythematosus and systemic sclerosis).

Pier Mannuccio Mannucci1, Massimo Vanoli, Ileana Forza, Maria Teresa Canciani, Raffaella Scorza.   

Abstract

BACKGROUND AND OBJECTIVES: Autoantibodies inactivating the von Willebrand factor (VWF) cleaving protease, ADAMTS-13, are among the most frequent causes of thrombotic thrombocytopenic purpura (TTP). We evaluated whether or not ADAMTS-13 deficiency and autoantibodies inactivating the protease prevalent in patients with the prototypic autoimmune diseases systemic lupus erythematosus (SLE) and systemic sclerosis (SSc). DESIGN AND METHODS: We measured, in parallel, the protease and VWF antigen (VWF:Ag) in 123 patients, 36 of whom had SLE and 87 of whom had SSc. In 14 patients with either disease who had low plasma protease levels (below 40%) we also looked for anti-ADAMTS-13 inactivating antibodies.
RESULTS: ADAMTS-13 levels were significantly lower in SLE (p=0.0013) and in SSc (p=0.0002) than in normal controls. No anti-ADAMTS activity was measurable in patients with low ADAMTS-13 levels. VWF:Ag was high in both SLE and SSc (p=0.001). INTERPRETATION AND
CONCLUSIONS: Systemic connective tissue diseases are other conditions besides TTP that are associated in some instances with low but detectable levels of ADAMTS-13. Autoantibodies inactivating protease activity are not the cause of the low plasma levels of ADAMTS-13.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12935979

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  23 in total

1.  Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo.

Authors:  S G Shelat; P Smith; J Ai; X L Zheng
Journal:  J Thromb Haemost       Date:  2006-08       Impact factor: 5.824

2.  Deficient activity of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura in the setting of adult-onset Still's disease.

Authors:  S Hirata; H Okamoto; S Ohta; T Kobashigawa; M Uesato; Y Kawaguchi; M Tateishi; M Hara; N Kamatani; H-M Tsai
Journal:  Rheumatology (Oxford)       Date:  2006-05-23       Impact factor: 7.580

3.  Why Do We Need ADAMTS13?

Authors:  Han-Mou Tsai
Journal:  Nihon Kessen Shiketsu Gakkai shi       Date:  2005

Review 4.  Biomarkers in systemic sclerosis.

Authors:  Susan V Castro; Sergio A Jimenez
Journal:  Biomark Med       Date:  2010-02       Impact factor: 2.851

5.  Nitrofurantoin-induced microangiopathic haemolytic anaemia and thrombocytopaenia in a patient with systemic lupus erythematosus.

Authors:  Linnette López-López; Noridza Rivera-Rodríguez; Luis M Vilá
Journal:  BMJ Case Rep       Date:  2012-09-12

6.  Breast Cancer-Associated Thrombotic Microangiopathy.

Authors:  Anne C Regierer; Dagmar Kuehnhardt; Carsten-Oliver Schulz; Bernd Flath; Christian F Jehn; Christian W Scholz; Kurt Possinger; Jan Eucker
Journal:  Breast Care (Basel)       Date:  2011-12-15       Impact factor: 2.860

7.  Endothelial Activation Markers as Disease Activity and Damage Measures in Juvenile Dermatomyositis.

Authors:  Takayuki Kishi; Jonathan Chipman; Melvina Evereklian; Khanh Nghiem; Maryalice Stetler-Stevenson; Margaret E Rick; Michael Centola; Frederick W Miller; Lisa G Rider
Journal:  J Rheumatol       Date:  2019-08-01       Impact factor: 4.666

8.  Von Willebrand factor, red cell fragmentation, and disease activity in systemic lupus erythematosus.

Authors:  Rodolfo V Curiel; Rajkumari Bhagati; Lakshmi Basavaraju; Delona Norton; James Katz; Elizabeth Haile; Arthur Weinstein
Journal:  HSS J       Date:  2008-07-01

9.  Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience.

Authors:  Paul Coppo; Michael Schwarzinger; Marc Buffet; Alain Wynckel; Karine Clabault; Claire Presne; Pascale Poullin; Sandrine Malot; Philippe Vanhille; Elie Azoulay; Lionel Galicier; Virginie Lemiale; Jean-Paul Mira; Christophe Ridel; Eric Rondeau; Jacques Pourrat; Stéphane Girault; Dominique Bordessoule; Samir Saheb; Michel Ramakers; Mohamed Hamidou; Jean-Paul Vernant; Bertrand Guidet; Martine Wolf; Agnès Veyradier
Journal:  PLoS One       Date:  2010-04-23       Impact factor: 3.240

Review 10.  Thrombotic thrombocytopenic purpura: a thrombotic disorder caused by ADAMTS13 deficiency.

Authors:  Han-Mou Tsai
Journal:  Hematol Oncol Clin North Am       Date:  2007-08       Impact factor: 3.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.